US Stock Insider Trading | Outset Medical disclosed 3 insider trading transactions on February 19

K-LinePoet · 2026-02-24T05:39:35+00:00

Outset Medical recently announced several insider transactions, including directors and executives selling shares on February 17, 2026. Trigg Leslie sold 3,361 shares, and other executives also engaged in similar transactions. The company focuses on dialysis technology to reduce costs and complexity.

K-LinePoet

2026-02-24 05:39:35

Abstract generation in progress

On February 19, 2026, Outset Medical (OM) disclosed three insider trading transactions. Director Trigg Leslie sold 3,361 shares on February 17, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 19, 2026	Executive	Nash Marc	February 17, 2026	Sell	1,817	3.35	6,086.95
February 19, 2026	Director	Trigg Leslie	February 17, 2026	Sell	3,361	3.35	13,300
February 19, 2026	Executive	Brottem John L.	February 17, 2026	Sell	2,842	3.35	9,520.70
January 21, 2026	Executive	Brottem John L.	January 21, 2026	Sell	1,180	5.01	5,911.80
January 21, 2026	Executive	Brottem John L.	January 20, 2026	Sell	9,314	5.12	47,700
January 21, 2026	Executive	Nash Marc	January 20, 2026	Sell	5,375	5.12	27,500
January 21, 2026	Director	Trigg Leslie	January 21, 2026	Sell	2,120	5.05	10,700
January 21, 2026	Director	Trigg Leslie	January 20, 2026	Sell	11,800	5.12	60,400
January 21, 2026	Executive	Nash Marc	January 21, 2026	Sell	980	4.98	4,880.40
January 8, 2026	Director	Trigg Leslie	January 7, 2026	Sell	1,795	4.27	7,664.65

[Company Profile]

Outset Medical, Inc. was initially incorporated on May 5, 2003, in Delaware under the name Home Dialysis Plus, Ltd. The company changed its name to Outset Medical, Inc. on January 5, 2015. It is a rapidly growing medical technology company that pioneered the use of similar technology to reduce the cost and complexity of dialysis. The company believes that the Tablo Hemodialysis System (Tablo) represents a significant technological advancement, enabling innovative and transformative dialysis care in both acute and home settings. From the outset, the company designed Tablo as a single enterprise solution that can be used throughout the care process, allowing anyone to perform dialysis anytime and anywhere.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.